Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2011, Article ID 740583, 7 pages
http://dx.doi.org/10.4061/2011/740583
Review Article

Three Types of Striational Antibodies in Myasthenia Gravis

1Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
2Department of Neurology, Hanamaki General Hospital, Hanamaki 025-0075, Japan

Received 28 April 2011; Accepted 3 June 2011

Academic Editor: Johan A. Aarli

Copyright © 2011 Shigeaki Suzuki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. N. Meriggioli and D. B. Sanders, “Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity,” The Lancet Neurology, vol. 8, no. 5, pp. 475–490, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. C. L. Williams and V. A. Lennon, “Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, α actinin, or actin,” Journal of Experimental Medicine, vol. 164, no. 4, pp. 1043–1059, 1986. View at Google Scholar · View at Scopus
  3. T. Yamamoto, T. Sato, and H. Sugita, “Antifilamin, antivinculin, and antitropomyosin antibodies in myasthenia gravis,” Neurology, vol. 37, no. 8, pp. 1329–1333, 1987. View at Google Scholar · View at Scopus
  4. M. Ohta, K. Ohta, N. Itoh, M. Kurobe, K. Hayashi, and H. Nishitani, “Anti-skeletal muscle antibodies in the sera from myasthenic patients with thymoma: identification of anti-myosin, actomysin, actin, and α-actinin antibodies by a solid-phase radioimmunoassay and a Western blotting analysis,” Clinica Chimica Acta, vol. 187, no. 3, pp. 255–264, 1990. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Aarli, A. K. Lefvert, and O. Tonder, “Thymoma-specific antibodies in sera from patients with myasthenia gravis demonstrated by indirect haemagglutination,” Journal of Neuroimmunology, vol. 1, no. 4, pp. 421–427, 1981. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Labeit, D. P. Barlow, M. Gautel et al., “A regular pattern of two types of 100-residue motif in the sequence of titin,” Nature, vol. 345, no. 6272, pp. 273–276, 1990. View at Publisher · View at Google Scholar · View at Scopus
  7. J. A. Aarli, K. Stefansson, L. S. G. Marton, and R. L. Wollmann, “Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin,” Clinical and Experimental Immunology, vol. 82, no. 2, pp. 284–288, 1990. View at Google Scholar · View at Scopus
  8. F. Romi, G. O. Skeie, N. E. Gilhus, and J. A. Aarli, “Striational antibodies in myasthenia gravis: reactivity and possible clinical significance,” Archives of Neurology, vol. 62, no. 3, pp. 442–446, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Gautel, A. Lakey, D. P. Barlow et al., “Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin,” Neurology, vol. 43, no. 8, pp. 1581–1585, 1993. View at Google Scholar · View at Scopus
  10. E. Lübke, A. Freiburg, G. O. Skeie et al., “Striational autoantibodies in myasthenia gravis patients recognize I- band titin epitopes,” Journal of Neuroimmunology, vol. 81, no. 1-2, pp. 98–108, 1998. View at Publisher · View at Google Scholar
  11. A. Mygland, O. B. Tysnes, R. Matre, P. Volpe, J. A. Aarli, and N. E. Gilhus, “Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma,” Annals of Neurology, vol. 32, no. 4, pp. 589–591, 1992. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Mygland, O. B. Tysnes, R. Matre, J. A. Aarli, and N. E. Gilhus, “Anti-cardiac ryanodine receptor antibodies in thymoma-associated myasthenia gravis,” Autoimmunity, vol. 17, no. 4, pp. 327–331, 1994. View at Google Scholar · View at Scopus
  13. S. Suzuki, T. Satoh, H. Yasuoka et al., “Novel autoantibodies to a voltage-gated potassium channel KV1.4 in a severe form of myasthenia gravis,” Journal of Neuroimmunology, vol. 170, no. 1-2, pp. 141–149, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. A. M. Yamamoto, P. Gajdos, B. Eymard et al., “Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients,” Archives of Neurology, vol. 58, no. 6, pp. 885–890, 2001. View at Google Scholar · View at Scopus
  15. M. Giraud, G. Beaurain, A. M. Yamamoto et al., “Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies,” Neurology, vol. 57, no. 9, pp. 1555–1560, 2001. View at Google Scholar · View at Scopus
  16. C. Buckley, J. Newsom-Davis, N. Willcox, and A. Vincent, “Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?” Neurology, vol. 57, no. 9, pp. 1579–1582, 2001. View at Google Scholar · View at Scopus
  17. X. J. Chen, J. Qiao, B. G. Xiao, and C. Z. Lu, “The significance of titin antibodies in myasthenia gravis: correlation with thymoma and severity of myasthenia gravis,” Journal of Neurology, vol. 251, no. 8, pp. 1006–1011, 2004. View at Google Scholar · View at Scopus
  18. F. Romi, J. A. Aarli, and N. E. Gilhus, “Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features,” European Journal of Neurology, vol. 14, no. 6, pp. 617–620, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Suzuki, K. Utsugisawa, Y. Nagane et al., “Classification of myasthenia gravis based on autoantibody status,” Archives of Neurology, vol. 64, no. 8, pp. 1121–1124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Suzuki, K. Utsugisawa, Y. Nagane, T. Satoh, M. Kuwana, and N. Suzuki, “Clinical and immunological differences between early and late-onset myasthenia gravis in Japan,” Journal of Neuroimmunology, vol. 230, pp. 148–152, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. J. A. Aarli, “Myasthenia gravis in the elderly: is it different?” Annals of the New York Academy of Sciences, vol. 1132, pp. 238–243, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Romi, E. K. Kristoffersen, J. A. Aarli, and N. E. Gilhus, “The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo,” Journal of Neuroimmunology, vol. 158, no. 1-2, pp. 191–194, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. G. O. Skeie, P. T. Bentsen, A. Freiburg, J. A. Aarli, and N. E. Gilhus, “Cell-mediated immune response against titin in myasthenia gravis: evidence for the involvement of Th1 and Th2 cells,” Scandinavian Journal of Immunology, vol. 47, no. 1, pp. 76–81, 1998. View at Publisher · View at Google Scholar
  24. F. Romi, G. O. Skeie, C. Vedeler, J. A. Aarli, F. Zorzato, and N. E. Gilhus, “Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis> A study of IgG subclasses and clinical correlations,” Journal of Neuroimmunology, vol. 111, no. 1-2, pp. 169–176, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. F. E. Somnier, G. O. Skeie, J. A. Aarli, and W. Trojaborg, “EMG evidence of myopathy and the occurrence of titin autoantibodies in patients with myasthenia gravis,” European Journal of Neurology, vol. 6, no. 5, pp. 555–563, 1999. View at Google Scholar · View at Scopus
  26. G. O. Skeie, A. Mygland, S. Treves, N. E. Gilhus, J. A. Aarli, and F. Zorzato, “Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro,” Muscle and Nerve, vol. 27, no. 1, pp. 81–89, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Nakata, S. Kuwabara, N. Kawaguchi et al., “Is excitation-contraction coupling impaired in myasthenia gravis?” Clinical Neurophysiology, vol. 118, no. 5, pp. 1144–1148, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Tsuda, T. Imai, T. Hozuki et al., “Correlation of bite force with excitation-contraction coupling time of the masseter in myasthenia gravis,” Clinical Neurophysiology, vol. 121, no. 7, pp. 1051–1058, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Imai, E. Tsuda, T. Toyoshima, H. Yoshikawa, M. Motomura, and S. Shimohama, “Anti-ryanodine receptor-positive acetylcholine receptor-negative myasthenia gravis: evidence of impaired excitation-contraction coupling,” Muscle and Nerve, vol. 43, no. 2, pp. 294–295, 2011. View at Publisher · View at Google Scholar
  30. M. Takamori, “Autoantibodies against TRPC3 and ryanodine receptor in myasthenia gravis,” Journal of Neuroimmunology, vol. 200, no. 1-2, pp. 142–144, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Maruta, H. Yoshikawa, S. Fukasawa et al., “Autoantibody to dihydropyridine receptor in myasthenia gravis,” Journal of Neuroimmunology, vol. 208, no. 1-2, pp. 125–129, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. K. M. Tan, V. A. Lennon, C. J. Klein, B. F. Boeve, and S. J. Pittock, “Clinical spectrum of voltage-gated potassium channel autoimmunity,” Neurology, vol. 70, no. 20, pp. 1883–1890, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Lai, M. G. M. Huijbers, E. Lancaster et al., “Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series,” The Lancet Neurology, vol. 9, no. 8, pp. 776–785, 2010. View at Publisher · View at Google Scholar
  34. A. Evoli, C. Minisci, C. Di Schino et al., “Thymoma in patients with MG: characteristics and long-term outcome,” Neurology, vol. 59, no. 12, pp. 1844–1850, 2002. View at Google Scholar · View at Scopus
  35. A. Mygland, G. Kuwajima, K. Mikoshiba, O. B. Tysnes, J. A. Aarli, and N. E. Gilhus, “Thymomas express epitopes shared by the ryanodine receptor,” Journal of Neuroimmunology, vol. 62, no. 1, pp. 79–83, 1995. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Marx, A. Wilisch, A. Schultz et al., “Expression of neurofilaments and of a titin epitope in thymic epithelial tumors. Implications for the pathogenesis of Myasthenia gravis,” American Journal of Pathology, vol. 148, no. 6, pp. 1839–1850, 1996. View at Google Scholar
  37. L. L. Kusner, A. Mygland, and H. J. Kaminski, “Ryanodine receptor gene expression thymomas,” Muscle and Nerve, vol. 21, no. 10, pp. 1299–1303, 1998. View at Publisher · View at Google Scholar · View at Scopus
  38. F. Romi, L. Bo, G. O. Skeie, A. Myking, J. A. Aarli, and N. E. Gilhus, “Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules,” Journal of Neuroimmunology, vol. 128, no. 1-2, pp. 82–89, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. C. L. Williams, J. E. Hay, T. W. Huiatt, and V. A. Lennon, “Paraneoplastic IgG striational autoantibodies produced by clonal thymic B cells and in serum of patients with myasthenia gravis and thymoma react with titin,” Laboratory Investigation, vol. 66, no. 3, pp. 331–336, 1992. View at Google Scholar
  40. M. Takamori, M. Motomura, N. Kawaguchi et al., “Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis,” Neurology, vol. 62, no. 10, pp. 1894–1896, 2004. View at Google Scholar · View at Scopus
  41. K. Iwasa, K. Komai, and M. Takamori, “Spontaneous thymoma rat as a model for myasthenic weakness caused by anti-ryanodine receptor antibodies,” Muscle and Nerve, vol. 21, no. 12, pp. 1655–1660, 1998. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Mygland, J. A. Aarli, R. Matre, and N. E. Gilhus, “Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis,” Journal of Neurology Neurosurgery and Psychiatry, vol. 57, no. 7, pp. 843–846, 1994. View at Google Scholar
  43. F. Romi, N. E. Gilhus, J. E. Varhaug, A. Myking, and J. A. Aarli, “Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study,” European Journal of Neurology, vol. 10, no. 6, pp. 701–706, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. F. Romi, G. O. Skeie, J. A. Aarli, and N. E. Gilhus, “The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies,” Archives of Neurology, vol. 57, no. 11, pp. 1596–1600, 2000. View at Google Scholar · View at Scopus
  45. A. Mygland, A. Vincent et al., “Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia,” Archives of Neurology, vol. 57, no. 4, pp. 527–531, 2000. View at Google Scholar
  46. S. Suzuki, K. Utsugisawa, H. Yoshikawa et al., “Autoimmune targets of heart and skeletal muscles in myasthenia gravis,” Archives of Neurology, vol. 66, no. 11, pp. 1334–1338, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. J. A. Aarli, “Herzmyasthenie: myasthenia of the heart,” Archives of Neurology, vol. 66, no. 11, pp. 1322–1323, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Sato, E. Iwasaki, S. Nogawa et al., “A patient with giant cell myocarditis and myositis associated with thymoma and myasthenia gravis,” Clinical Neurology, vol. 43, no. 8, pp. 496–499, 2003. View at Google Scholar · View at Scopus
  49. J. Tsugawa, Y. Tsuboi, H. Inoue, S. Suzuki, and T. Yamada, “Recurrent syncope due to sick sinus syndrome in a patient with myasthenia gravis associated with thymoma,” Clinical Neurology, vol. 51, no. 1, pp. 32–34, 2011. View at Google Scholar
  50. K. Nakamura, Y. Katayama, K. F. Kusano et al., “Anti-KCNH2 Antibody-Induced Long QT Syndrome. Novel Acquired Form of Long QT Syndrome,” Journal of the American College of Cardiology, vol. 50, no. 18, pp. 1808–1809, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Nagane, S. Suzuki, N. Suzuki, and K. Utsugisawa, “Factors associated with response to calcineurin inhibitors in myasthenia gravis,” Muscle and Nerve, vol. 41, no. 2, pp. 212–218, 2010. View at Publisher · View at Google Scholar · View at Scopus